Towards a better method of cannabinoid extraction and preservation for cannabis-based products
; Pascual, Ana Clara
; Milano, Pablo Gustavo
; Bocetti, Marisol Claudia ; Pasquaré, Susana Juana Otros responsables
Fecha
2020
Editorial
Fundación Revista Medicina
Revista
Título del libro
Nombre del evento
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimenta; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Fecha del evento
2019-11-13
Institución organizadora
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Asociación Argentina de Nanomedicinas
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Asociación Argentina de Nanomedicinas
ISSN
0025-7680
eISSN
1669-9106
ISBN
Idioma
Inglés
Tipo del evento
Reunión
Clasificación temática
Palabras clave
Resumen
Recombinant human erythropoietin (Epo) has been successful in the treatment of anemia of different etiologies but high Epo doses, used to reduce the frequency of administration or to treat refractory anemia, have been linked with adverse outcomes. Previously, we observed a decreased effect of high Epo concentrations on endothelial cell migration. Here, we studied the antiapoptotic effect of Epo on erythroleukemia K562 cells exposed to TNF-a (T), after incubation with increasing concentrations of Epo (10, 100 and 400 U/mL) and erythroid differentiation with hemin. While Epo10 prevented the increase in the percentage of apoptotic nuclei observed with TNF-a, Epo100 and Epo400 did not show that protection. Considering that this effect could be related to the decreased availability of the Epo receptor, we investigated the activity of protein tyrosine phosphatase 1B (PTP1B) and the process of proteasomal degradation in this cell model. PTP1B activity, which regulates many aspects of the signaling pathways elicited by Epo upon EpoR activation, showed no significant differences between cultures with low and high Epo concentrations. Then, we used the proteasome inhibitor MG132 to evaluate if EpoR internalization could affect the antiapoptotic effect of Epo against TNF-a. In the presence of MG132, the results with high concentrations of Epo were similar to those observed with Epo10T (Hoechst staining, C 13.5 ± 0.7, T 31.5 ± 1.5*, Epo10T 22.1 ± 1.1*, Epo100T 29.4 ± 1.4*, Epo400T 29.9 ± 2.2*, Epo100TMG 21.7 ± 19, and Epo400TMG 22 ± 1.3 %, *P<0.05, n= 6). Based on this, it can be suggested that the kinetics of EpoR internalization/degradation, mediated by the proteasome, could explain, at least in part, the lack of antiapoptotic effect of high concentrations of Epo. The present results give new insights that may contribute to understand Epo behavior when cells of different tissues are activated by a high concentration of the hormone, and may help to adequate therapeutic strategies.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
